Biosimilars Market Overview

The biosimilars market has been experiencing rapid growth in recent years, driven by the increasing demand for cost-effective alternatives to biologic drugs, which are often prohibitively expensive. Biosimilars, which are highly similar versions of approved reference biologics, offer similar therapeutic benefits while reducing healthcare costs. The market is valued at USD 24.50 billion in 2024 and is expected to grow at a compound annual growth rate (CAGR) of 17.60% from 2025 to 2034. By 2034, the biosimilars market is projected to reach USD 123.95 billion.

The primary drivers of this market expansion are the rising prevalence of chronic diseases, the growing aging population, and the increasing regulatory approvals of biosimilars across various regions. Additionally, advancements in biotechnology, coupled with growing healthcare spending in both developed and emerging markets, are contributing significantly to the overall growth of the biosimilars market.

Market Size

In 2024, the  biosimilars market size is estimated to be USD 24.50 billion. This robust valuation reflects the increased acceptance of biosimilars by both healthcare professionals and patients. The market is expected to experience significant growth over the forecast period, driven by the escalating need for cost-effective treatments, the expiration of patents for blockbuster biologics, and the increasing availability of biosimilars in the market.

By 2034, the biosimilars market is projected to expand to USD 123.95 billion, which represents a remarkable CAGR of 17.60%. As more biosimilars gain regulatory approval, especially for diseases such as cancer, diabetes, and autoimmune disorders, the market is expected to witness substantial investment and innovation.

Market Share

The biosimilars market is segmented into different product types, drug classes, indications, and regions, creating a diversified market landscape. The global market share of biosimilars is dominated by a few key players, including pharmaceutical companies that focus on the development of biosimilars for both oncology and chronic conditions like diabetes and rheumatoid arthritis.

In terms of product types, recombinant glycosylated proteins and recombinant non-glycosylated proteins make up a significant portion of the biosimilars market. Additionally, certain drug classes such as monoclonal antibodies, insulin, and granulocyte colony-stimulating factors are highly prevalent in the biosimilars segment.

Get a free sample request: https://www.expertmarketresearch.com/reports/biosimilar-market/requestsample

Market Trends

• Increasing Regulatory Approvals: As more biosimilars receive regulatory approvals from agencies like the U.S. FDA and the European Medicines Agency (EMA), the market is expected to expand. Approval of biosimilars for complex indications, such as cancer and autoimmune diseases, is a significant trend fueling market growth.
• Cost-Effectiveness: One of the key driving factors for the adoption of biosimilars is the cost-effectiveness they offer compared to their reference biologics. This has resulted in a growing shift toward biosimilars, particularly in countries with high healthcare expenditure.
• Expanding Indications: While biosimilars were initially developed for chronic diseases like diabetes, their indications have expanded to treat complex conditions such as oncology, autoimmune disorders, and blood disorders.
• Patent Expirations of Biologics: The patent expiration of several high-cost biologics, such as monoclonal antibodies and insulin, has created a favorable environment for biosimilars. This trend is expected to continue in the forecast period.
• Increasing Healthcare Access in Emerging Markets: As healthcare access improves in emerging markets, biosimilars are gaining popularity due to their affordability, especially in regions such as Asia-Pacific, Latin America, and Africa.

Market Analysis

The biosimilars market is witnessing significant growth due to a combination of factors, including regulatory advancements, cost advantages, and improved healthcare access. Companies in the biosimilars market are increasingly investing in developing high-quality, affordable alternatives to expensive biologics.

The market has seen increased investment from both established pharmaceutical companies and new entrants. Biosimilars are expected to continue evolving with the development of more complex treatments for oncology, autoimmune diseases, and genetic disorders. Furthermore, with a growing number of biologics losing patent protection, the market opportunities for biosimilars are expanding globally.

While the market faces challenges such as regulatory hurdles, patent disputes, and the complexities involved in biosimilar development, the long-term prospects remain strong. Increasing awareness, technological innovations, and healthcare reforms are likely to address these barriers, paving the way for continued growth.

Market Segmentation

• Breakup by Product Type:
  • Recombinant Glycosylated Proteins: These biosimilars mimic biologic drugs that require glycosylation (the attachment of sugar molecules to proteins). This segment is significant in the biosimilars market due to its broad application in oncology and autoimmune diseases.
  • Recombinant Non-Glycosylated Proteins: These biosimilars are simpler in structure and do not require glycosylation, which makes them more accessible and cost-effective for several therapeutic applications.
• Breakup by Drug Class:
  • Insulin: A major class of biosimilars used in the treatment of diabetes. As the demand for insulin rises globally, especially in emerging markets, this segment is expected to grow significantly.
  • Recombinant Human Growth Hormone (RHGH): Used to treat growth hormone deficiencies, this biosimilar is widely accepted in pediatric and adult patients.
  • Granulocyte Colony-Stimulating Factor: A class of biosimilars used to boost white blood cell production in cancer patients.
  • Interferon: Used in the treatment of hepatitis and multiple sclerosis, this class of biosimilars is increasingly popular in both the developed and emerging markets.
  • Erythropoietin: Used for anemia treatment, especially for chronic kidney disease patients, erythropoietin biosimilars are gaining widespread usage.
  • Etanercept: A biosimilar used for autoimmune diseases like rheumatoid arthritis.
  • Monoclonal Antibodies: This class holds the largest market share in the biosimilars industry, with drugs like adalimumab and trastuzumab driving market growth.
  • Others: Includes other biosimilars like follitropin, glucagon, calcitonin, teriparatide, and enoxaparin sodium, each with specific indications and therapeutic uses.
• Breakup by Indications:
  • Chronic Diseases: Includes diseases like diabetes and arthritis, where biosimilars can provide significant cost savings and improve accessibility to treatments.
  • Oncology: A rapidly expanding area for biosimilars, with monoclonal antibodies and granulocyte colony-stimulating factors being commonly used.
  • Autoimmune Diseases: Includes diseases like rheumatoid arthritis and psoriasis, where biologic therapies are being replaced by biosimilars.
  • Infectious Diseases: The demand for biosimilars in infectious diseases, particularly HIV and hepatitis, is increasing.
  • Blood Disorders: Erythropoietin biosimilars are widely used for blood disorders like anemia in chronic kidney disease.
  • Growth Hormone Deficiency: Growth hormone biosimilars are widely used in pediatric growth hormone deficiencies.
• Breakup by Procedure:
  • Invasive: Some biosimilars require injections or other invasive methods to administer, especially those for oncology and chronic diseases.
  • Non-Invasive: Non-invasive biosimilars can be administered orally or through patches, providing easier and more accessible treatment options.
• Breakup by Region:
  • North America: The largest market, driven by high healthcare expenditure and demand for affordable biologics.
  • Europe: A rapidly growing market for biosimilars, particularly in countries with advanced healthcare systems.
  • Asia Pacific: Expected to see the highest CAGR, as biosimilars become more accessible and in-demand in countries like India and China.
  • Latin America: A growing biosimilars market, with increasing government support for affordable medications.
  • Middle East and Africa: An emerging market for biosimilars, driven by improving healthcare infrastructure.

Market Growth

The biosimilars market is poised for strong growth due to increasing acceptance, favorable regulatory environments, and the rising demand for affordable alternatives to high-cost biologic drugs. As the biosimilars landscape evolves, more treatments for chronic diseases and complex conditions such as cancer are expected to emerge, boosting market expansion.

Recent Developments and Challenges in the Market

Recent advancements include regulatory approvals for monoclonal antibody biosimilars, with major pharmaceutical companies investing in the development of biosimilars for oncology and autoimmune disorders. However, challenges remain, such as patent disputes, market entry barriers, and the complex nature of biologic drug development.

Key Players

• Novartis AG
• Orion Pharma
• Pfizer Inc.
• Samsung Bioepis
• Coherus BioSciences, Inc.
• Amgen Inc.
• Eli Lilly and Company
• Takeda Pharmaceutical Company Limited
• Bristol-Myers Squibb Company
• Merck KGaA
• Teva Pharmaceutical Industries Ltd.
• Biocon
• Bayer AG
• AbbVie Inc.
• Allergan
• Dr. Reddy’s Laboratories Ltd.
• Boehringer Ingelheim International GmbH
• Biogen

FAQs

Q: What are biosimilars?

A1: Biosimilars are biologic medical products highly similar to an already-approved reference biologic drug. They offer the same therapeutic effects but are typically more affordable.

Q: How are biosimilars different from generic drugs?

A2: Unlike generics, which are identical copies of small-molecule drugs, biosimilars are similar, but not identical, to reference biologics due to the complexity of biologic molecules.

Q: Why is the biosimilars market growing rapidly?

A3: The growth is driven by the increasing demand for affordable biologics, the patent expiry of major biologic drugs, and the rising prevalence of chronic diseases and cancer.

Q: Which biosimilar drug classes are most popular?

A4: Monoclonal antibodies, insulin, and granulocyte colony-stimulating factors are among the most popular biosimilar drug classes.

Q: Which regions are driving biosimilars market growth?

A5: North America and Europe remain the largest markets, but the Asia-Pacific region is expected to experience the highest growth due to expanding healthcare access and demand for affordable drugs.